Relato de caso – eventos neuromusculares relacionados com inibidores de checkpoint
DOI:
https://doi.org/10.34024/rnc.2022.v30.12780Palavras-chave:
Miastenia gravis, miopatia, neuropatia, imunoterapia, anti-pd1, melanoma, neoplasia, câncerResumo
O melanoma invasivo possui alta mortalidade e sua incidência tem aumentado nos últimos anos de forma considerável. A descoberta dos inibidores de checkpoint (ICP), melhorou significativamente o prognóstico do tratamento, aumentando sobrevida e qualidade de vida dos pacientes com essas neoplasias. Embora a eficácia comprovada desses tratamentos tenha mudado a história natural do melanoma, vários efeitos colaterais foram relatados, principalmente relacionados ao sistema imunológico. O objetivo desse estudo é descrever um caso de eventos neuromusculares sobrepostos de miopatia, miastenia gravis e neuropatia periférica após início de tratamento com anti-PD1 (Nivolumab) em um paciente com melanoma invasivo.
Downloads
Métricas
Referências
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet 2018;392:971-84. https://doi.org/10.1016/S0140-6736(18)31559-9
Herrscher H, Robert C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol 2020;32:106-13. https://doi.org/10.1097/cco.0000000000000610
Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806-12.
https://doi.org/10.1097/wco.0000000000000391
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:1721-8. https://doi.org/10.1001/jamaoncol.2018.3923
Kao JC, Brickshawana A, Liewluck T. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep 2018;18:63. https://doi.org/10.1007/s11910-018-0878-7
Johansen A, Christensen SJ, Scheie D, Højgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. Neurology 2019;92:663-74. https://doi.org/10.1212/wnl.0000000000007235
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016;2:234-40. https://doi.org/10.1001/jamaoncol.2015.4368
Touat M, Maisonobe T, Knauss S, Hadj B, Salem O, Hervier B, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018;91:e985-94. https://doi.org/10.1212/wnl.0000000000006124
Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation 2018;138:743-5. https://doi.org/10.1161/circulationaha.118.035898
Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019;48:736-40. https://doi.org/10.1016/j.semarthrit.2018.05.006
Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 2019;100:105-13.
https://doi.org/10.1016/j.jaut.2019.03.005
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12-23. https://doi.org/10.1016/j.ejca.2018.09.033
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017;82:128-36. https://doi.org/10.1016/j.ejca.2017.05.041
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127-34. https://doi.org/10.1212/wnl.0000000000004359
Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854-68. https://doi.org/10.1093/cvr/cvz026
Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 2019;130:1440-5. https://doi.org/10.1016/j.clinph.2019.03.035
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95. https://doi.org/10.1186/s40425-017-0300-z
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.
https://doi.org/10.1200/jco.2017.77.6385
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 2019;17:255-89. https://doi.org/10.6004/jnccn.2019.0013
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Mariana Queiroz Borges, Ellen Camila Rodrigues Dias , Zeno Augusto de Sousa Neto, Mariana Resende Guedes, Ábner Pereira Prado, Marcos Alexandre Diniz Carneiro
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Aceito: 2021-12-06
Publicado: 2022-01-25